Antiphospholipid antibodies in critically ill patients with cancer: A prospective cohort study

Journal of Critical Care

Volumn 29, Issue 4, 2014, Pages 533-538

  Vassalo, Juliana ^a   Spector, Nelson ^a   de Meis, Ernesto ^b   Rabello, Lígia S C F ^a,b   Rosolem, Maíra M ^b   do Brasil, Pedro E A A ^c,d   Salluh, Jorge I F ^a,b,c   Soares, Márcio ^a,b,c  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^c D OR INSTITUTE FOR RESEARCH AND EDUCATION IDOR   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Antiphospholipid antibodies; Cancer; Intensive care unit; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; ANTITHROMBIN; BETA2 GLYCOPROTEIN 1 ANTIBODY; D DIMER; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C; BETA2 GLYCOPROTEIN 1; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ANTIBODY TITER; ARTICLE; BLEEDING; CANCER CENTER; CANCER PATIENT; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HEMATOLOGIC MALIGNANCY; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIAN SIMPLIFIED ACUTE PHYSIOLOGY SCORE 3; MORTALITY; NEUROLOGIC DISEASE; PROGNOSIS; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; SCORING SYSTEM; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SOLID TUMOR; VASCULAR DISEASE; BLOOD; CONFIDENCE INTERVAL; CRITICAL ILLNESS; HEMATOLOGIC DISEASE; IMMUNOLOGY; MIDDLE AGED; NEOPLASM; PROPORTIONAL HAZARDS MODEL;

AGED; ANTIBODIES, ANTIPHOSPHOLIPID; BETA 2-GLYCOPROTEIN I; CONFIDENCE INTERVALS; CRITICAL ILLNESS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMATOLOGIC NEOPLASMS; HUMANS; INTENSIVE CARE UNITS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; SEPSIS;

EID: 84902283026     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2014.02.005     Document Type: Article

References (33)

1. Levine J.S., Branch D.W., Rauch J. The antiphospholipid syndrome. N Engl J Med 2002, 346:752-763.
2. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
3. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011, 7:330-339.
4. Asherson R.A. The catastrophic antiphospholipid syndrome. J Rheumatol 1992, 19:508-512.
5. Asherson R.A., Cervera R., de PG, Erkan D., Boffa M.-C., Piette J.-C., et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003, 12:530-534.
6. Blom J.W., Doggen C.J.M., Osanto S., Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005, 293:715-722.
7. De Meis E., Pinheiro V.R., Loures M.A.L., Kotouc M.M., Zamboni M.M., Guedes M.T.S., et al. Lupus anticoagulant activity as a thrombosis risk factor in lung adenocarcinoma patients. Ann N Y Acad Sci 2007, 1107:51-55.
8. Miesbach W., Scharrer I., Asherson R. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol 2006, 25:840-844.
9. Tincani A., Taraborelli M., Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun Rev 2010, 9:200-202.
10. Font C., Vidal L., Espinosa G., Tàssies D., Monteagudo J., Farrús B., et al. Solid cancer, antiphospholipid antibodies, and venous thromboembolism. Autoimmun Rev 2011, 10:222-227.
11. Wenzel C., Stoiser B., Locker G.J., Laczika K., Quehenberger P., Kapiotis S., et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med 2002, 30:763-770.
12. Aldawood A.S., Crowther M., Jaeschke R., Dabbagh O., Alkhairy K., Baharoon S., et al. The incidence and impact of lupus anticoagulants among patients in the intensive care unit. Saudi Med J 2005, 26:1994-1995.
13. Salluh J.I.F., Soares M., Meis E.D. Antiphospholipid antibodies and multiple organ failure in critically ill cancer patients. Clinics 2009, 64:79-82.
14. Moreno R.P., Metnitz P.G.H., Almeida E., Jordan B., Bauer P., Campos R.A., et al. SAPS 3 Investigators: SAPS 3-from evaluation of the patient to evaluation of the intensive care unit. Part 2: development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med 2005, 31:1345-1355.
15. Vincent J.L., Moreno R., Takala J., Willatts S., De Mendonça A., Bruining H., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710.
16. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
17. Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., et al. Infectious Diseases Society of America: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52:e56-e93.
18. Taylor F.B., Toh C.H., Hoots W.K., Wada H., Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH): towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86:1327-1330.
19. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982, 69:239-241.
20. Blank M., Krause I., Fridkin M., Keller N., Kopolovic J., Goldberg I., et al. Bacterial induction of autoantibodies to β2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002, 109:797-804.
21. Pierangeli S.S., Blank M., Liu X., Espinola R., Fridkin M., Ostertag M.V., et al. A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo. J Autoimmun 2004, 22:217-225.
22. Shoenfeld Y., Blank M., Cervera R., Font J., Raschi E., Meroni P.-L. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 2006, 65:2-6.
23. Willis R., Harris E.N., Pierangeli S.S. Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost 2012, 38:305-321.
24. Sidelmann J.J., Sjøland J.A., Gram J., Bertelsen V., Mourits-Andersen T., Münster H., et al. Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis. Scand J Clin Lab Invest 2007, 67:270-279.
25. Bećarević M., Majkić-Singh N. High-sensitivity C-reactive protein: discriminator between patients with primary and secondary antiphospholipid syndrome. Clin Biochem 2008, 41:1449-1453.
26. Piette J.C., Cacoub P., Wechsler B. Renal manifestations of the antiphospholipid syndrome. Semin Arthritis Rheum 1994, 23:357-366.
27. Cervera R., Bucciarelli S., Plasín M.A., Gómez-Puerta J.A., Plaza J., Pons-Estel G., et al. Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum On Antiphospholipid Antibodies): catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun 2009, 32:240-245.
28. Uthman I., Khamashta M. Antiphospholipid syndrome and the kidneys. Semin Arthritis Rheum 2006, 35:360-367.
29. Espinosa G., Cervera R., Asherson R.A. Catastrophic antiphospholipid syndrome and sepsis. A common link?. J Rheumatol 2007, 34:923-926.
30. Shorr A.F., Trotta R.F., Alkins S.A., Hanzel G.S., Diehl L.F. D-dimer assay predicts mortality in critically ill patients without disseminated intravascular coagulation or venous thromboembolic disease. Intensive Care Med 1999, 25:207-210.
31. Levi M., van der Poll T., Schultz M. Systemic versus localized coagulation activation contributing to organ failure in critically ill patients. Semin Immunopathol 2012, 34:167-179.
32. Querol-Ribelles J.M., Tenias J.M., Grau E., Querol-Borras J.M., Climent J.L., Gomez E., et al. Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest 2004, 126:1087-1092.
33. Salluh J.I., Rabello L.S., Rosolem M.M., Soares M., Bozza F.A., Verdeal J.C., et al. The impact of coagulation parameters on the outcomes of patients with severe community-acquired pneumonia requiring intensive care unit admission. J Crit Care 2011, 26:496-501.